{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:32:41Z","timestamp":1789824761723,"version":"4.0.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":3139,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018787","name":"Novartis Animal Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic kidney disease (CKD) is an important cause of morbidity and mortality in dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy in prolonging survival and safety of benazepril administration to dogs with CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Forty-nine client-owned dogs with CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Dogs were randomized to benazepril (0.25 to &amp;lt;0.5\u00a0mg\/kg) or placebo once daily for up to 2\u00a0years in a prospective, multicenter, blinded clinical trial. The primary endpoint variable was the renal survival time, defined as the time from inclusion in the study to the treatment failure endpoint of death or euthanasia or need for administration of parenteral fluids related to renal failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No benefit of benazepril versus placebo was detected for renal survival time in all dogs; median (95% confidence interval (CI)) survival times were 305 (53\u2013575) days in the benazepril group and 287 (152-not available) in the placebo group (P\u00a0=\u00a0.53). Renal survival times were not significantly longer with benazepril compared to placebo for subgroups: hazard ratios (95% CI) were 0.50 (0.21\u20131.22) with P\u00a0= .12 for initial urine protein-to-creatinine ratio (UPC) &amp;gt;0.5, and 0.38 (0.12\u20131.19) with P\u00a0=\u00a0.080 for initial UPC &amp;gt;0.5 plus plasma creatinine \u2264440\u00a0\u03bcmol\/L. Proteinuria, assessed from the UPC, was significantly (P\u00a0= .0032) lower after treatment with benazepril compared to placebo. There were no significant differences between groups for clinical signs or frequencies of adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Relevance<\/jats:title>\n                    <jats:p>Benazepril significantly reduced proteinuria in dogs with CKD. Insufficient numbers of dogs were recruited to allow conclusions on survival time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.14726","type":"journal-article","created":{"date-parts":[[2017,7,2]],"date-time":"2017-07-02T00:06:35Z","timestamp":1498953995000},"page":"1113-1122","source":"Crossref","is-referenced-by-count":10,"title":["Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo-Controlled Clinical Trial"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4194-9015","authenticated-orcid":false,"given":"J.N.","family":"King","sequence":"first","affiliation":[{"name":"Elanco Animal Health , Basel,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Font","sequence":"additional","affiliation":[{"name":"Hospitar Ars Veterinaria , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-F.","family":"Rousselot","sequence":"additional","affiliation":[{"name":"Clinique v\u00e9t\u00e9rinaire du Clos des Cam\u00e9lias , Colombes,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Ash","sequence":"additional","affiliation":[{"name":"Grove Lodge Veterinary Group , Brighton,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Bonfanti","sequence":"additional","affiliation":[{"name":"La Vallon\u00e8a Veterinary Diagnostic Laboratory , Alessano,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Brovida","sequence":"additional","affiliation":[{"name":"ANUBI Ospedale per Animali da Compagnia , Moncalieri\/Torino,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.D.","family":"Crowe","sequence":"additional","affiliation":[{"name":"Kingsway Veterinary Group , Skipton,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lanore","sequence":"additional","affiliation":[{"name":"Clinique V\u00e9t\u00e9rinaire Alliance , Bordeaux,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Pechereau","sequence":"additional","affiliation":[{"name":"Hopital Purpan , Pau,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Seewald","sequence":"additional","affiliation":[{"name":"Elanco Animal Health , Basel,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Strehlau","sequence":"additional","affiliation":[{"name":"Elanco Animal Health , Basel,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,7,1]]},"reference":[{"key":"2026020303200094900_jvim14726-bib-0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1090-0233(97)80048-2","article-title":"Pathophysiology and management of progressive renal disease","volume":"154","author":"Brown","year":"1997","journal-title":"Vet J"},{"key":"2026020303200094900_jvim14726-bib-0002","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"2026020303200094900_jvim14726-bib-0003","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","author":"GISEN Group","year":"1997","journal-title":"Lancet"},{"key":"2026020303200094900_jvim14726-bib-0004","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2885.2004.00614.x","article-title":"Angiotensin-converting enzyme inhibitors in the therapy of renal diseases","volume":"27","author":"Lefebvre","year":"2004","journal-title":"J Vet Pharmacol Therap"},{"key":"2026020303200094900_jvim14726-bib-0005","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1939-1676.2000.tb02271.x","article-title":"Effects of enalapril versus placebo as a treatment for canine idiopathic glomerulonephritis","volume":"14","author":"Grauer","year":"2000","journal-title":"J Vet Intern Med"},{"key":"2026020303200094900_jvim14726-bib-0006","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4314\/ovj.v6i2.8","article-title":"The effect of renal diet in association with enalapril or benazepril on proteinuria in dogs with proteinuric chronic kidney disease","volume":"6","author":"Zatelli","year":"2016","journal-title":"Open Vet J"},{"key":"2026020303200094900_jvim14726-bib-0007","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0021-9975(97)80016-3","article-title":"Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor","volume":"117","author":"Grodecki","year":"1997","journal-title":"J Comp Pathol"},{"key":"2026020303200094900_jvim14726-bib-0008","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2460\/ajvr.2003.64.321","article-title":"Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency","volume":"64","author":"Brown","year":"2003","journal-title":"Am J Vet Res"},{"key":"2026020303200094900_jvim14726-bib-0009","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1292\/jvms.70.455","article-title":"Development of hypertension and effects of benazepril hydrochloride in a canine remnant kidney model of chronic renal failure","volume":"70","author":"Mishina","year":"2008","journal-title":"J Vet Med Sci"},{"key":"2026020303200094900_jvim14726-bib-0010","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2460\/javma.234.8.1031","article-title":"A randomized controlled clinical trial of the use of benazepril and heparin for the treatment of chronic kidney disease in dogs","volume":"234","author":"Tenh\u00fcndfeld","year":"2009","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303200094900_jvim14726-bib-0011","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1745-6215-11-32","article-title":"CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials","volume":"11","author":"Schulz","year":"2010","journal-title":"Trials"},{"key":"2026020303200094900_jvim14726-bib-0012","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1760-2734(06)70025-X","article-title":"The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a prospective, randomized, double-blinded, placebo-controlled clinical trial","volume":"1","author":"The BENCH (Benazepril in Canine Heart Disease) Study Group","year":"1999","journal-title":"J Vet Cardiol"},{"key":"2026020303200094900_jvim14726-bib-0013","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1939-1676.1999.tb02160.x","article-title":"Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites","volume":"13","author":"Lefebvre","year":"1999","journal-title":"J Vet Intern Med"},{"key":"2026020303200094900_jvim14726-bib-0014","article-title":"2013 Treatment recommendations for CKD in dogs","author":"IRIS"},{"key":"2026020303200094900_jvim14726-bib-0015","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/j.1939-1676.2006.tb00702.x","article-title":"Tolerability and efficacy of benazepril in cats with chronic kidney disease","volume":"20","author":"King","year":"2006","journal-title":"J Vet Intern Med"},{"key":"2026020303200094900_jvim14726-bib-0016","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1046\/j.1523-1755.2001.0600031131.x","article-title":"Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease","volume":"60","author":"Jafar","year":"2001","journal-title":"Kidney Int"},{"key":"2026020303200094900_jvim14726-bib-0017","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2460\/javma.2005.226.393","article-title":"Evaluation of the association between initial proteinuria and morbidity rate or death in dogs with naturally occurring chronic renal failure","volume":"226","author":"Jacob","year":"2005","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303200094900_jvim14726-bib-0018","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/vr.162.5.141","article-title":"Associations between proteinuria, systemic hypertension and glomerular filtration rate in dogs with renal and non-renal diseases","volume":"162","author":"Wehner","year":"2008","journal-title":"Vet Rec"},{"key":"2026020303200094900_jvim14726-bib-0019","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2460\/javma.2003.222.322","article-title":"Association between initial systolic blood pressure and risk of developing a uremic crisis or of dying in dogs with chronic renal failure","volume":"222","author":"Jacob","year":"2003","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303200094900_jvim14726-bib-0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1155\/S1173912603000178","article-title":"Robustness to non-normality of common tests for the many-sample location problem","volume":"7","author":"Khan","year":"2003","journal-title":"J App Math Dec Sci"},{"key":"2026020303200094900_jvim14726-bib-0021","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/00007890-199709270-00021","article-title":"Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients","volume":"64","author":"Morrone","year":"1997","journal-title":"Transplantation"},{"key":"2026020303200094900_jvim14726-bib-0022","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1939-1676.2007.tb03042.x","article-title":"Prognostic factors in cats with chronic kidney disease","volume":"21","author":"King","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020303200094900_jvim14726-bib-0023","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1939-1676.2008.0163.x","article-title":"Survival in cats with naturally occurring chronic kidney disease (2000-2002)","volume":"22","author":"Boyd","year":"2008","journal-title":"J Vet Intern Med"},{"key":"2026020303200094900_jvim14726-bib-0024","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1939-1676.2011.00874.x","article-title":"Clinicopathological variables predicting progression of azotemia in cats with chronic kidney disease","volume":"26","author":"Chakrabarti","year":"2012","journal-title":"J Vet Intern Med"},{"key":"2026020303200094900_jvim14726-bib-0025","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0272-6386(03)00905-3","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2026020303200094900_jvim14726-bib-0026","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2460\/javma.245.10.1135","article-title":"Prognostic role of the product of serum calcium and phosphorus concentrations in dogs with chronic kidney disease: 31 cases (2008\u20132010)","volume":"245","author":"Lippi","year":"2014","journal-title":"J Am Vet Med Assoc"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.14726","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/31\/4\/1113\/66668487\/jvim14726.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/31\/4\/1113\/66668487\/jvim14726.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:20:13Z","timestamp":1770106813000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/31\/4\/1113\/8449384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,1]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.14726","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,7]]},"published":{"date-parts":[[2017,7,1]]}}}